单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases, Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China.
Antiviral drugs on influenza are important in the control program of influenza. Options for influenza treatment are currently limited to using the neuraminidase inhibitors (NAIs). Given limited effectiveness of NAIs and related resistance, there remains an urgent need for the development of influenza antiviral drugs that can improve the efficacy and provide low propensity of viral resistance. Several influenza-related antiviral drugs that are currently under the late-stage clinical trials all appear differently in the mechanism of action. It is hoped that when new antiviral drugs are licensed, care and outcomes of severe influenza cases will be improved.
语种：
中文
PubmedID：
第一作者：
第一作者单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases, Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China.
推荐引用方式(GB/T 7714)：
Wang Y M,Cao B.Perspectives of antiviral drugs used on influenza[J].Chinese Journal of Epidemiology.2018,39(8):1051-1059.
